OS Therapies Inc (NYSE-A:OSTX) shares jumped 12.4% following favorable feedback from the FDA regarding its OST-HER2 treatment ...

"With the advent of anti-HER2 therapy in metastatic colorectal cancer, the key question for HER2-amplified RAS/BRAF wild-type tumors is who should be preferentially treated with therapy directed ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

We've all usually just continued the treatment, but there is a study ongoing, called STOP-HER2, which is taking people who have been on HER2-directed therapy without any disease progression for at ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

The most common treatment for HER2-positive breast cancer is chemotherapy plus HER2-directed therapy. This is followed by surgery, then continues with HER2-directed therapy.

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Anti-HER2 therapies: treatments that target and block the HER2 protein, which can promote the growth of cancer cells, often used in breast cancer treatment. Circulating tumor DNA: small fragments of ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.